Occlusive retinal vasculitis associated with systemic sclerosis and antiphospholipid antibodies

Caleb C. Ng \textsuperscript{a,b,*}, Sandip Suresh \textsuperscript{c}, James T. Rosenbaum \textsuperscript{c,d,e}, H. Richard McDonald \textsuperscript{a,b}, Emmett T. Cunningham Jr. \textsuperscript{a,b,f,g}

\textsuperscript{a} West Coast Retina Medical Group, San Francisco, CA, USA
\textsuperscript{b} The Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA
\textsuperscript{c} Department of Ophthalmology, Oregon Health and Science University, Portland, OR, USA
\textsuperscript{d} Department of Medicine, Oregon Health and Science University, Portland, OR, USA
\textsuperscript{e} Legacy Devers Eye Institute, Portland, OR, USA
\textsuperscript{f} The Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA
\textsuperscript{g} The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, CA, USA

ARTICLE INFO

Keywords:
Cardiolipin
B2 glycoprotein
CREST syndrome
Phosphotidylserine
Retinal ischemia
Scleroderma

ABSTRACT

Purpose: To report a series of patients with occlusive retinal vasculitis associated with systemic sclerosis (SSc) and elevated antiphospholipid antibody titers.

Method: Case series. Main outcome measures included clinical and fluorescein angiographic findings at presentation and over time.

Observations: Case 1 - A 61-year-old woman initially diagnosed with idiopathic, bilateral panuveitis and retinal vasculitis causing peripheral nonperfusion was subsequently diagnosed with limited cutaneous systemic sclerosis (lcSSc). Her ocular inflammation and retinal vasculitis were controlled with topical and periocular corticosteroids, but she eventually developed peripheral retinal vascular occlusion that progressed to macular ischemia 11 years after presentation. Repeat serologic evaluation detected interval development of antiphospholipid antibodies. Case 2 – A 58-year-old woman was found to have bilateral peripheral nonperfusion and retinal neovascularization in her right eye. Given her elevated hemoglobin A1c of 8.5%, she was diagnosed with presumed proliferative diabetic retinopathy. Three years after initial presentation, she was diagnosed with lcSSc. Subsequent serum workup detected elevated B2-glycoprotein antibody titers. Her peripheral nonperfusion progressed despite adequate glycemic control, resulting in further neovascularization in each eye. Case 3 – A 40-year-old woman with diffuse cutaneous systemic sclerosis (dcSSc) and elevated titers of anti-cardiolipin antibodies developed multiple branch retinal artery occlusions with subsequent neovascularization of the retina, optic disc, and angle in the right eye.

Conclusion and Importance: Vision-threatening occlusive retinal vasculitis may develop in select patients with SSc. The presence of elevated anti-phospholipid antibody titers may confer increased risk for this vision-threatening complication.

1. Introduction

Scleroderma describes a group of related connective tissue diseases of unknown etiology that can be localized, such as in morphea, linear Scleroderma, linear scleroderma en coup de sabre (CDS), and progressive hemifacial atrophy (PHA; Parry-Romberg syndrome), or systemic with involvement of internal organs, as seen in limited cutaneous systemic sclerosis (lcSSc; formerly CREST syndrome; comprised of Calcinosi, Raynaud’s phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and diffuse cutaneous systemic sclerosis (dcSSc). \textsuperscript{1,2} Occlusive retinal vasculitis is a rare complication of scleroderma that has been described in two patients with lcSSc \textsuperscript{3} and one patient with both PHA and CDS. \textsuperscript{4} We present three additional patients with vision-threatening occlusive retinal vasculitis who were found to have either lcSSc or dcSSc in conjunction with elevated antiphospholipid antibody titers.

* Corresponding author. Retina Consultants of Orange County, 301 W. Bastanchury Rd. #285, Fullerton, CA, 92835, USA.
E-mail address: Calebctng@gmail.com (C.C. Ng).
2. Case 1

A 61-year-old Asian woman was found to have optic disc hyperemia and isolated peripheral intraretinal hemorrhages in her left eye. Fluorescein angiography (FA) revealed optic disc and vascular leakage with scattered areas of peripheral nonperfusion in the left eye. Extensive serum evaluation for infectious, autoimmune, and coagulopathy markers, including antiphospholipid antibodies, was unremarkable, but her hemoglobin A1c (6.5%) and cholesterol levels were elevated. On subsequent examination two years later, the patient was noted to have mild, bilateral anterior chamber and vitreous inflammation. Repeat FA showed diffuse vascular leakage with patchy peripheral areas of nonperfusion in both eyes (Fig. 1 – A, B) and formation of small vessel telangiectasias in the mid-periphery of the left eye (Fig. 1 – C, D). The patient was diagnosed with bilateral panuveitis with occlusive retinal vasculitis from an unknown etiology, and was treated with topical corticosteroid eyedrops and intermittent intravitreal sustained-release dexamethasone implants. Approximately nine years after presentation, the patient developed a non-healing ulcer on her left index finger, prompting a workup that eventually led to the diagnosis of incomplete lcSSc, based on presence of sclerodactyly, finger ischemia (Fig. 2), telangiectasias, and dysphagia. No serum rheumatologic aberrations were identified. Two years later, the patient’s vision declined from 20/32 and 20/40 to 20/80 and 20/63 in the right and left eyes, respectively. She was found to have moderate anterior chamber inflammation and macular edema with cotton wool spots in each eye (Fig. 3 – A, B). Fluorescein angiography identified leakage of the vessels, optic disc, and macula, and areas of capillary nonperfusion in the nasal macula and periphery in both eyes (Fig. 3 – C, D). Extensive serum evaluation for rheumatologic markers found elevated titers of cardiolipin (IgM) and phosphatidylserine (IgM) antibodies.

3. Case 2

A 58-year-old Caucasian woman with systemic hypertension and a 25-year history of type II diabetes mellitus was referred for evaluation of bilateral retinal hemorrhages. Examination of her posterior segment revealed scattered microaneurysms and intraretinal hemorrhages in the periphery of each eye, and an area of neovascularization with...
surrounding cotton wool spots in the nasal mid-periphery of the right eye. Fluorescein angiography showed leakage consistent with neovascularization, and peripheral capillary nonperfusion on the right. Since her hemoglobin A1c was elevated (8.5%), she was presumed to have non-proliferative retinopathy of the left eye and proliferative diabetic retinopathy of the right eye, prompting panretinal photocoagulation (PRP) on the right. Three years after initial presentation, she was diagnosed with incomplete lcSSc, based on diffuse scattered telangiectasias, sclerodactyly, a history of Raynaud’s phenomenon, and positive anti-centromere antibody titers. Despite maintenance of glycemic control with A1c ranging from 6.5% to 7.5% over the next seven years, she developed recurrent vitreous hemorrhages in the right eye that were treated with intravitreal bevacizumab injections, and worsening peripheral non-perfusion (Fig. 4A) and eventual neovascularization of the peripheral retina and optic disc in the left eye (Fig. 4B). On subsequent rheumatologic testing, she was found to have elevated titers of beta-2 glycoprotein 1 (IgM) antibodies.

4. Case 3

A 40-year-old woman with history of systemic hypertension and dcSSc that was diagnosed based on a history of sclerodactyly, non-healing skin ulcers, esophageal dysmotility, interstitial lung disease, and Raynaud’s phenomenon was referred for decreased vision in both eyes. Her visual acuity was HM in the right eye and 20/60 in the left. Intraocular pressures were normal. Anterior segment examination revealed diffuse neovascularization of the angle in the right eye, and posterior segment examination revealed numerous branch retinal artery occlusions and a small preretinal hemorrhage in the right eye and intraretinal hemorrhages in the left eye (Fig. 5A). She denied any hearing loss. Anti-
cardiolipin antibody titers were strongly positive. Fluorescein angiography confirmed the presence of multiple branch retinal artery occlusions, and also revealed optic disc neovascularization and extensive peripheral nonperfusion (Fig. 5B). She was treated with PRP on the right, which controlled her proliferative retinopathy.

5. Discussion

We present three cases of occlusive retinal vasculitis associated with systemic sclerosis (SSc) and elevated antiphospholipid titers (see Table 1). Two of the three of patients also had elevated Hg A1c levels and an equal number had systemic hypertension. Bilateral involvement was present in two patients, resulting in five affected eyes. All eyes were found to have intraretinal hemorrhages and peripheral capillary nonperfusion, with retinal neovascularization also present in three eyes, macular non-perfusion in two eyes, and neovascularization of the disc and angle in one eye.

The diagnosis of SSc is established from careful clinical examination, antibody testing, and ancillary testing. On initial and subsequent examinations, the skin is examined for thickening, fingertip lesions, telangiectasia, abnormal nail fold capillaries, and the Raynaud phenomenon. Close monitoring of blood pressure is also required as baseline or new-onset systemic hypertension may indicate renal involvement. Serial assessment of urine protein content is another means of monitoring renal function. A chest computed tomography scan should be obtained to assess for evidence of interstitial lung disease or a dilated, air-filled esophagus from long-standing esophageal dysmotility. Earlier disease can be detected by means of pulmonary function testing, endoscopy, esophageal manometry, and barium swallow studies. A transthoracic echocardiography should be obtained when there is suspicion for pulmonary arterial hypertension or pericardial effusion. More than 90% of the cases of SSc will have elevated titers of anti-nuclear antibodies. Patients with SSc may also possess either anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA polymerase III, or anti-U3-RNP (fibrillarin) antibodies. Of these, a positive anti-centromere titer is specific to lcSSc, whereas the presence of the other three are associated with dcSSc. A patient is diagnosed with the lcSSc when the manifestations of SSc are limited to calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.

While SSc is a long-recognized autoimmune condition, with reported prevalence of 242–443 cases per million adults in North America, associated occlusive retinal vasculitis appears to be rare with only two cases reported previously by Yang and colleagues in 2018. Since early manifestations of SSc may be difficult to diagnose, particularly when lcSSc, and the ocular manifestations may pre-date the systemic diagnosis, it could be that some patients with SSc and occlusive retinal vasculitis go unrecognized for some time, as with our Case 1, or the retinal findings may be ascribed to more common causes, such as diabetic retinopathy, particularly when seen in the setting of elevated Hg A1c levels, as in Cases 1 and 2. Moreover, peripheral retinal non-perfusion was challenging to diagnose prior to routine imaging of

**Table 1**

Summary of case histories, clinical findings, and treatments.

| Case | 1 | 2 | 3 |
|------|---|---|---|
| **Age (years)** | 61 | 58 | 40 |
| **Gender** | F | F | F |
| **Initial VA** | 20/32 OD, 20/40 OS | 20/20 OD, 20/25 OS | HM OD, 20/60 OS |
| **Scleroderma subtype** | lcSSC | lcSSC | dcSSC |
| **Comorbidities (duration in years)** | Type II Diabetes Mellitus (11) | Type II Diabetes Mellitus (32) | Systemic hypertension (?) |
| **Location of Capillary Non-perfusion** | Macula and Peripheral Retina OU | Peripheral Retina OU | Peripheral Retina OD |
| **Presence/Location of Neovascularization** | None | Periphery OU | Angle, Periphery, and Optic Disc OD |
| **Elevated Antiphospholipid Antibodies (isotype)** | Cardiolipin (IgM) and Phosphotidylserine (IgM) | Beta-2 glycoprotein 1 (IgM) | Cardiolipin (N/A) |
| **Treatment** | Topical corticosteroids; Sustained-release dexamethasone implant; Oral corticosteroids; 225 mg ASA PO/day | PRP OD; IVT Bevacizumab OU; Oral corticosteroids; 225 mg ASA PO/day | PRP OD |
| **Final VA** | 20/50 OD, 20/63 OS (pseudophakic OU) | 20/25 OD, 20/16 OS | N/A |

F = female, VA = visual acuity, OD = right eye, OS = left eye, lcSSC = limited cutaneous systemic sclerosis, dcSSC = diffuse cutaneous systemic sclerosis, ? = unknown, OU = both eyes, ASA = acetylsalicylic acid, PO = taken by mouth, PRP = panretinal photocoagulation, IVT = intravitreal, N/A = not available.
the peripheral retina with wide-field fluorescein angiography.

While our cases resembled those reported by Yang et al. we show here for the first time a history of progressive retinal nonperfusion despite adequate control of retinal vascular leakage as in Case 1, development of proliferative retinopathy as in cases 2 and 3, and the presence of potentially occlusion-promoting antiphospholipid antibodies in all three cases.5-7 One of the patients described by Yang5 was contributed by a co-author (JTR) of this report, but she differed from the patients in our series as she tested negative for phospholipid antibodies and lupus anti-coagulant. These antibodies, which target cardiolipin, beta-2 glycoprotein 1, and phosphatidylserine, are common in patients with systemic lupus erythematosus (SLE), but they also occur in patients with other autoimmune diseases such as SSc or in individuals with no other apparent autoimmunity.7 Paradoxically, antibodies that cause clotting in vivo can prolong the partial thromboplastin time in vitro - a phenomenon known as the lupus anticoagulant. In a dated, but still important, longitudinal study from Stafford-Brady et al.8 patients with SLE and the lupus anticoagulant were more likely to develop cotton wool spots. Antiphospholipid antibody testing should be considered, therefore, in any patient who develops an occlusive retinal arterial or venular vasculopathy in the absence of infection, especially if the leukocyte response in the anterior chamber or vitreous humor is mild or absent.

Our series highlights possible therapeutic approaches to the management of occlusive retinal vasculitis associated with SSc. Use of regional corticosteroids was effective in halting the vascular leakage in Case 1, but the patient’s non-perfusion progressed and eventually involved the macula, raising the question of whether long-term corticosteroid-sparing immunosuppressant therapy would have prevented this complication. While no therapy exists to alter the course of scleroderma, a variety of disease-modifying agents, such as cyclophosphamide, mycophenolate mofetil, methotrexate, azathioprine, and hydroxychloroquine, have been reported to have efficacy in reducing the severity of skin and lung manifestations. However, little is known about the role of immunosuppressant therapy in management of scleroderma-related ocular disease. In patients with proliferative retinopathy, PRP can both treat and lower the risk of vision loss related to retinal neovascularization and neovascular glaucoma. While anti-VEGF agents may play a role in some such cases, we and others have reported catastrophic retinal vascular occlusion following intravitreal bev-acizumab injection in eyes with multiple risk factors for retinal vascular occlusion, including diabetes mellitus, systemic hypertension, and SSc,9 suggesting that these agents should be used with caution in such vulnerable patients. Patients with elevated antiphospholipid titers may be at higher risk for deep vein thromboses, pulmonary embolism, and non-bacterial thrombotic endocarditis.1 The management can be complex, therefore, and may involve the use of anti-coagulants, anti-platelet agents, and biologics, especially rituximab.10 After the retinal findings for Case 1 and 2 were relayed to rheumatology, both patients were treated with high-dose oral corticosteroids and a daily 325 mg dose of acetylsalicylic acid; more potent anticoagulation was recommended for the management of occlusive retinal vasculitis associated with PHA/CDS was 17 years of age.5 Isolated reports of retinal vascular leakage, central retinal artery occlusion, and central retinal vein occlusion related to PHA have also appeared in patients within the first two decades of life, half of whom also possessed CDS.2,13

Given that occlusive retinal vasculitis associated with SSc is a rare and difficult condition to diagnosis, alternate causes of ischemic retinal vasculitis should be considered. Ischemic retinal vasculitis has been described in patients with tuberculosis hypersensitivity, West Nile virus infection, Behçet’s disease, sarcoidosis, multiple sclerosis, systemic lupus erythematosus, Takayasu’s disease, idiopathic retinal vasculitis, dermatomyositis, Churg-Strauss syndrome, Crohn’s disease, Polyarteritis nodosa, and Susac syndrome.14

In summary, vision-threatening occlusive retinal vasculitis may develop in select patients with SSc and the presence of elevated anti-phospholipid antibody titers may confer increased risk for this complication. Patient with otherwise unexplained retinal vasculitis, including nonperfusion, should be asked about signs or symptoms that might suggest SSc or the related conditions of PHA/CDS, and should be tested for the presence of anti-phospholipid antibodies. Regional corticosteroids appear to be effective at controlling both active inflammation and retinal vascular leakage, whereas PRP has been used effectively to both treat and limit the loss of vision loss related to retinal neovascularization and neovascular glaucoma. The role of longer-term non-corticosteroid immunosuppressive therapy remains to be studied.

Patient consent

Patients in case 1 and 2 consented to the publication of the case in writing. The patient in case 3 is deceased at the time of this report, and no consent was able to be obtained.

Funding

San Francisco Retina Foundation.

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Declaration of competing interest

None of the authors have any financial disclosures.

Acknowledgments

None.

References

1. Adigun R, Goyal A, Bansal P, Hariz A. Systemic Sclerosis (CREST Syndrome). StatPears [Internet]. 2020. Apr 28.
2. Tolkachjov SN, Patel NG, Tollefson MM. Progressive hemifacial atrophy: a review. Orphanet J Rare Dis. 2015;10(1):1–3. Dec.
3. Yang S, Koplin LJ, Rosenshan JT. Retinal vasculitis associated with CREST syndrome. American journal of ophthalmology case reports. 2018;10:185–188. Jun 1.
4. Vata A, Gevorgyan O, De D, Hassan S. Retinal vasculitis: the first clue in the diagnosis of progressive hemifacial atrophy. European journal of rheumatology. 2019;6(4):219. Oct.
5. Merabi M, Ames PR. Clinical relevance of antiphospholipid antibodies in systemic sclerosis: a systematic review and meta-analysis. Apr 1 Semin Arthritis Rheum. 2017; 46(5):615–624. WB Saunders.
6. Sobanski V, Lemaire-Olivier A, Giovannelli J, et al. Prevalence and clinical associations of antiphospholipid antibodies in systemic sclerosis: new data from a French cross-sectional study. Semin Arthritis Rheum. 2018;48:2457. Nov 2.
7. Giannakopoulou B, Krimis S. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033–1044. Mar 14.
8. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum. 1988;31:1105–1110.
9. Ng C.C., Brill D., Cunningham E.T. Jr, Burckhard B.A., Jumper J.M., Heier J., Rifkin L.M., Elliott D., McDonald H.R., Sobrin L. Catastrophic, bilateral retinal vascular occlusion after intravitreal bevacizumab injection. Retin Cases Brief Rep. 2021 May 10. doi: 10.1097/ICB.0000000000001158. Epub ahead of print. PMID: 33988542.

10. Cohen H, Cuadrado MJ, Erkan D, et al. 16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Lupus. 2020;29(12):1571–1593. Oct.

11. Agmon-Levin N, Berman M, Harel I, et al. Rituximab for refractory manifestations of the antiphospholipid syndrome: a multicentre Israeli experience. Clin Exp Rheumatol. 2020. Oct 27. Epub ahead of print. PMID: 33124581.

12. Khamaganova I. Progressive hemifacial atrophy and linear scleroderma en coup de sabre: a spectrum of the same disease? Front Med. 2018;4:258. Jan 31.

13. Ehmann D, Biyar R, Greve M. Central retinal artery occlusion in a child with Parry–Romberg syndrome. Can J Ophthalmol. 2014;49(1):e9–10. Feb 1.

14. Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its management, 2014 J Ophthalmol. 2014:197675. https://doi.org/10.1155/2014/197675. Epub 2014 Apr 15. PMID: 24839552; PMCID: PMC4009272.